Genedrive Regulatory News (GDR)

genedrive plc

("genedrive" or the "Company")

Total Voting Rights

genedrive plc (AIM:GDR), the point of care molecular diagnostics company, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 6 April 2023 the Company's issued share capital consists of 99,049,946 Ordinary Shares of 1.5p each. This follows the Admission today of 6,500,000 Ordinary Shares of 1.5p each further to the Company's announcement on 31 March 2023 including details of a £5m Equity Prepayment Facility.

The total number of voting rights in the Company is 99,049,946 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further details please contact:

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.

The Genedrive® MT-RNR1 ID Kit, selected as 1 of the 10 EVA pilot projects, is the world's first commercial point-of-care genetic test for emergency care. It helps to avoid irreversible lifelong hearing loss in specific infants exposed to aminoglycosides by rapidly detecting the m.1555A>G gene variant that can cause lifelong deafness, allowing for alternative antibiotics to be prescribed. Product information can be found at https://www.genedrive.com/assays/rnr1-product.php